← Leaderboards
Philip D. Harvey
Mount Sinai School Of Medicine Of Nyu
$8,229,485
Attributed
$17,502,790
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$17,502,790 · 7
By mechanism
R01$16,640,455 · 4
R43$450,000 · 1
R21$412,335 · 1
P50$0 · 1
Top collaborators
- Terry Goldberg7 shared
- Lon S Schneider7 shared
- David Lewis Penn5 shared
- Amy Pinkham5 shared
- Sara J. Czaja4 shared
- Peter Kallestrup2 shared
- David Loewenstein2 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Jonine Lisa Bernstein$38,646,945
- Albert L Siu$4,771,561
- Robin Herbert$4,986
Others in their field
Top investigators on “Schizophrenia”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$104,668,216
- Raquel E Gur · University Of Pennsylvania$60,189,770
- Mark J Daly · Broad Institute, Inc.$48,989,393
- John M Kane · Long Island Jewish Medical Center$45,235,871
- Carrie E Bearden · University Of California Los Angeles$42,025,230
- Scott W Woods · Yale University$41,221,536
Research focus
SchizophreniaBaseCognitiveSamplingImpairmentCognitionPerformanceImpaired CognitionAlzheimer&AposDesignSocialOutcome MeasureFunctional OutcomesMonitorInstrumentStructureAttentionResearch PersonnelSitePsychosocialRandomizedSkillsInformantPsychometrics
Grant awards (27)
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$2,109,311
R01 · FY2022 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$2,080,252
R01 · FY2021 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,505,130
R01 · FY2020 · AG
Novel Cognitive and Functional Measures for Alzheimer's Disease Prevention Trials: Sensitivity to Biomarkers$637,919
R01 · FY2020 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$400,184
R01 · FY2020 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,505,129
R01 · FY2019 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,595,795
R01 · FY2018 · AG
A novel computer-based functional skills assessment and training program$225,000
R43 · FY2018 · AG
A novel computer-based functional skills assessment and training program$225,000
R43 · FY2017 · AG
Social Cognition Psychometric Evaluation$674,260
R01 · FY2016 · MH · contact PI
Social Cognition Psychometric Evaluation$657,409
R01 · FY2015 · MH · contact PI
Social Cognition Psychometric Evaluation$623,088
R01 · FY2014 · MH · contact PI
Social Cognition Psychometric Evaluation$666,944
R01 · FY2013 · MH · contact PI
Improving the Functional Outcomes in Older Adults with Schizophrenia$144,585
R21 · FY2013 · AG
Social Cognition Psychometric Evaluation$592,201
R01 · FY2012 · MH · contact PI
Improving the Functional Outcomes in Older Adults with Schizophrenia$267,750
R21 · FY2012 · AG
Validation of Measures of real-world outcome$340,808
R01 · FY2011 · MH · contact PI
Validation of Measures of real-world outcome$344,250
R01 · FY2010 · MH · contact PI
Validation of Measures of real-world outcome$344,250
R01 · FY2009 · MH · contact PI
Validation of Measures of real-world outcome$344,250
R01 · FY2008 · MH · contact PI
Course of Functional Deficits in Late-Life Schizophrenia$361,613
R01 · FY2007 · MH · contact PI
Validation of Measures of real-world outcome$344,250
R01 · FY2007 · MH · contact PI
Course of Functional Deficits in Late-Life Schizophrenia$372,414
R01 · FY2006 · MH · contact PI
Course of Functional Deficits in Late-Life Schizophrenia$381,375
R01 · FY2005 · MH
Course of Functional Deficits in Late-Life Schizophrenia$381,375
R01 · FY2004 · MH
Course of Functional Deficits in Late-Life Schizophrenia$378,248
R01 · FY2003 · MH
Core--Clinical$0
P50 · FY2002 · MH